ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Predicting Recovery After Joint Bleeding in Persons With Bleeding Disorders.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionJoint bleeds are burdensome and recovery differs from bleed to bleed. Identifying predictors of recovery could enable personalized treatment and monitoring; aiming to prevent long-term joint deterioration, and facilitate faster return to activities.
aimTo identify predictors of time to recovery after joint bleeding in people with haemophilia.
methodsRegular care data on recovery of joint bleeds were collected from people with haemophilia who attended the Van Creveldkliniek between 2016 and 2025. The primary outcome was time to recovery, defined as the normalization of all clinical symptoms. Kaplan-Meier survival curves and Cox proportional hazard regression were conducted. Independent variables were as follows: trough level, joint status, cause of the bleed, joint location, limitation in ROM, effusion on ultrasound, time between start of symptoms and start of treatment, treatment days and emicizumab treatment.
resultsSixty-four bleeds in 44 individuals were included. Most of the patients had haemophilia A (87.9%). Median time to recovery was 32.5 days. Joint bleeds without limitation in range of motion (<15 degrees limitation in flexion or extension) at presentation recovered 2.3 times faster (p = 0.007) than bleeds with a limitation. Patients with severe haemophilia A on emicizumab prophylaxis recovered 2.7 times faster than those on factor-prophylaxis (p = 0.027).
conclusionJoint bleeds with significant limitation in ROM at presentation needed more time to recover. Patients with severe haemophilia on emicizumab showed shorter recovery after joint bleeding. Follow-up should be personalized and extended beyond one month.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.